Rac1b: An emerging therapeutic target for chemoresistance in colorectal cancer

[1]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[2]  P. Chaturvedi,et al.  RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer , 2019, Molecular Cancer Therapeutics.

[3]  J. Utikal,et al.  Loss of neural crest‐associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation , 2018, International journal of cancer.

[4]  Hanchen Xu,et al.  Drug resistance and new therapies in colorectal cancer , 2018, World journal of gastroenterology.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  S. Cook,et al.  Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors , 2018, Cells.

[7]  P. Jordan,et al.  The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression , 2018, Oncogene.

[8]  You-hong Cui,et al.  RAC1-GTP promotes epithelial-mesenchymal transition and invasion of colorectal cancer by activation of STAT3 , 2018, Laboratory Investigation.

[9]  C. González-Billault,et al.  Crosstalk between Rac1-mediated actin regulation and ROS production. , 2018, Free radical biology & medicine.

[10]  V. Mittal.  Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.

[11]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[12]  D. Witte,et al.  Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b , 2017, Scientific Reports.

[13]  M. Kazanietz,et al.  The Rac GTPase in Cancer: From Old Concepts to New Paradigms. , 2017, Cancer research.

[14]  Maria João M Bugalho,et al.  RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells , 2017, PloS one.

[15]  D. Bates,et al.  Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer , 2017, Oncotarget.

[16]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[17]  A. Malliri,et al.  Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms , 2016, Small GTPases.

[18]  A. Porter,et al.  Deregulation of Rho GTPases in cancer , 2016, Small GTPases.

[19]  Hong Wang,et al.  Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways , 2016, Oncotarget.

[20]  J. Swensen,et al.  High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine , 2016, Familial Cancer.

[21]  William A. Hammond,et al.  Pharmacologic resistance in colorectal cancer: a review , 2016, Therapeutic advances in medical oncology.

[22]  M. Moyer,et al.  Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells. , 2015, Cancer letters.

[23]  Robert Brown,et al.  TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..

[24]  M. Ahmadian,et al.  Critical off‐target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets , 2015, Journal of thrombosis and haemostasis : JTH.

[25]  E. Goka,et al.  Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression , 2015, Oncogene.

[26]  C. Der,et al.  Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease , 2014, Oncogene.

[27]  P. Jares,et al.  RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. , 2014, European journal of cancer.

[28]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[29]  K. Oda,et al.  Matrix Metalloproteinase (MMP)-9 in Cancer-Associated Fibroblasts (CAFs) Is Suppressed by Omega-3 Polyunsaturated Fatty Acids In Vitro and In Vivo , 2014, PloS one.

[30]  P. Houghton,et al.  RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis , 2013, Molecular Cancer Therapeutics.

[31]  Gabriela Kalna,et al.  ROS Production and NF-κB Activation Triggered by RAC1 Facilitate WNT-Driven Intestinal Stem Cell Proliferation and Colorectal Cancer Initiation , 2013, Cell stem cell.

[32]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[33]  B. Al-Lazikani,et al.  Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance , 2012, Clinical pharmacology and therapeutics.

[34]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[35]  D. Radisky,et al.  Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial–mesenchymal transition , 2012, Molecular biology of the cell.

[36]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[37]  J. Field,et al.  PAK signaling in cancer , 2012, Cellular logistics.

[38]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[39]  L. Cubano,et al.  Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase* , 2012, The Journal of Biological Chemistry.

[40]  S. Licciulli,et al.  The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis , 2012, Oncogene.

[41]  J. Bertoglio,et al.  The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1. , 2011, Developmental cell.

[42]  E. Giannoni,et al.  Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. , 2011, Antioxidants & redox signaling.

[43]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[44]  David A. Williams,et al.  Rac GTPases in Human Diseases , 2010, Disease markers.

[45]  P. Johnston,et al.  Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer , 2010, Clinical Cancer Research.

[46]  D. Radisky,et al.  The 19-Amino Acid Insertion in the Tumor-associated Splice Isoform Rac1b Confers Specific Binding to p120 Catenin* , 2010, The Journal of Biological Chemistry.

[47]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[49]  Robin P Boushey,et al.  Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. , 2009, Clinics in colon and rectal surgery.

[50]  C. Oliveira,et al.  Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding. , 2009, Bioorganic & medicinal chemistry letters.

[51]  Xiaoren Zhang,et al.  NF-κB Signaling Pathway, Inflammation and Colorectal Cancer , 2009, Cellular and Molecular Immunology.

[52]  R. Seruca,et al.  B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. , 2008, Gastroenterology.

[53]  P. Baumann,et al.  Alkylating agents induce activation of NFκB in multiple myeloma cells , 2008 .

[54]  P. Jordan,et al.  Increased Rac1b Expression Sustains Colorectal Tumor Cell Survival , 2008, Molecular Cancer Research.

[55]  L. Samson,et al.  DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. , 2008, The Journal of clinical investigation.

[56]  C. Der,et al.  Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.

[57]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[58]  P. Catalano,et al.  Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy , 2007, Clinical Cancer Research.

[59]  S. Madhusudan,et al.  Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. , 2007, Cancer treatment reviews.

[60]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[61]  G. Casey,et al.  Role of IKK and oscillatory NFκB kinetics in MMP‐9 gene expression and chemoresistance to 5‐fluorouracil in RKO colorectal cancer cells , 2007, Molecular carcinogenesis.

[62]  B. Bapat,et al.  Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells. , 2007, Cancer research.

[63]  Lei Wang,et al.  Cell type-specific functions of Rho GTPases revealed by gene targeting in mice. , 2007, Trends in cell biology.

[64]  P. Jordan,et al.  Rac1, but Not Rac1B, Stimulates RelB-mediated Gene Transcription in Colorectal Cancer Cells* , 2006, Journal of Biological Chemistry.

[65]  B. Kaina,et al.  Rho GTPases: promising cellular targets for novel anticancer drugs. , 2006, Current cancer drug targets.

[66]  T. Taverne,et al.  RAC1 Inhibition Targets Amyloid Precursor Protein Processing by γ-Secretase and Decreases Aβ Production in Vitro and in Vivo* , 2005, Journal of Biological Chemistry.

[67]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[68]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[69]  H. Schmoll,et al.  (Neo-)adjuvant treatments in colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  P. Jordan,et al.  Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression. , 2005, Experimental cell research.

[71]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[72]  E. Lengyel,et al.  Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation , 2004, Oncogene.

[73]  Kevin M. Ryan,et al.  Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells , 2004, Cancer Research.

[74]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[75]  L. Moldawer,et al.  Inducible nuclear factor-κB activation contributes to chemotherapy resistance in gastric cancer1 ☆ , 2004 .

[76]  T. Conroy,et al.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Kazuhiro Takahashi,et al.  Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.

[78]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[79]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  B. Hemmings,et al.  Advances in protein kinase B signalling: AKTion on multiple fronts. , 2004, Trends in biochemical sciences.

[81]  Radovan Dvorsky,et al.  Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase* , 2004, Journal of Biological Chemistry.

[82]  John G. Collard,et al.  Tumor-related Alternatively Spliced Rac1b Is Not Regulated by Rho-GDP Dissociation Inhibitors and Exhibits Selective Downstream Signaling* , 2003, Journal of Biological Chemistry.

[83]  C. Gélinas,et al.  To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis , 2003, Oncogene.

[84]  Y. Kaneda,et al.  Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. , 2003, Experimental cell research.

[85]  H. McLeod,et al.  Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines , 2003, International journal of cancer.

[86]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[87]  K. Preissner,et al.  Rho protein inactivation induced apoptosis of cultured human endothelial cells. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[88]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[89]  M. Rothenberg.  Efficacy of oxaliplatin in the treatment of colorectal cancer. , 2000, Oncology.

[90]  E. Lengyel,et al.  Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b , 2000, Oncogene.

[91]  G. Peters,et al.  Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  P. Jordan,et al.  Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors , 1999, Oncogene.

[93]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[94]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[95]  Kenji Nakamura,et al.  Rac1 is required for the formation of three germ layers during gastrulation , 1998, Oncogene.

[96]  J. Jackson,et al.  Structural Requirements for PAK Activation by Rac GTPases* , 1998, The Journal of Biological Chemistry.

[97]  P. Rougier,et al.  Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. , 1998, Seminars in oncology.

[98]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[99]  N. Baldini.  Multidrug resistance — a multiplex phenomenon , 1997, Nature Medicine.

[100]  V. Ferrans,et al.  rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappaB activation , 1996, Molecular and cellular biology.

[101]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[102]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[103]  B. Williams,et al.  Identification and characterization of human beta 2-chimaerin: association with malignant transformation in astrocytoma. , 1995, Cancer research.

[104]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[105]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[106]  C. Heidelberger,et al.  Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[107]  M. Moyer,et al.  Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b. , 2013, Neoplasia.

[108]  P. Wigmore,et al.  Effects of 5-FU. , 2010, Advances in experimental medicine and biology.

[109]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[110]  Lawrence N Kwong,et al.  APC and its modifiers in colon cancer. , 2009, Advances in experimental medicine and biology.

[111]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[112]  F. Oakley,et al.  Nuclear factor-?B1: Regulation and function , 2008 .

[113]  M. Ahmadian,et al.  Purification and biochemical properties of Rac1, 2, 3 and the splice variant Rac1b. , 2006, Methods in enzymology.

[114]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[115]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[117]  P. Laurent-Puig.  [Genetic alterations in colorectal cancer]. , 1994, Annales de pathologie.